» Articles » PMID: 19128761

[Improvement of Intestinal Function in Cystic Fibrosis Patients Using Probiotics]

Overview
Specialty Pediatrics
Date 2009 Jan 9
PMID 19128761
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In some cases, cystic fibrosis may include intestinal inflammation and bacterial overgrowth. Probiotics are considered as immunomodulatory, anti-inflammatory and microbiotic regulator substances. The aim of our study is to determine the prevalence of bacterial overgrowth in cystic fibrosis patients and try to improve the intestinal function with the administration of probiotics.

Patients And Method: We examined 20 patients with cystic fibrosis (mean age 10.33, range 5 to 17 years). The expired hydrogen test with a 2 g/kg of 20% dextrose overload was performed on 10 patients. After the test, Lactobacillus rhamnosus LGG 10(11) CFU was administered twice daily for four weeks. Faecal near infrared spectroscopy (FENIR) of water, fat, nitrogen and sugar content in faeces was performed before and after probiotics administration.

Results: Five patients (50%) showed bacterial overgrowth. We obtained a positive correlation between the hydrogen test and steatorrhea (R = 0.57) and sugar in faeces (R = 0.52). The FENIR results pre-treatment vs post-treatment were: fat 6.2 g +/- 3.3 g vs. 4.9 g +/- 2.1 g (p < 0.05), sugar 6.7 +/- g 3.6 g vs. 5 g +/- 2.6 g (p < 0.05) and nitrogen 0.87 g +/- 0.27 g vs. 0.91 g +/- 0.14 g (NS) respectively. Thirteen patients (81.25%) had improved stool appearance and intestinal comfort and nine (56.25%) decreased the number of daily stools.

Conclusions: Probiotics improved not only clinical but also biochemical intestinal function in cystic fibrosis patients. These could be given as a regular treatment in this type of patients and in those with bacterial overgrowth.

Citing Articles

Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis.

Ray K, Santee C, McCauley K, Panzer A, Lynch S BMC Pulm Med. 2022; 22(1):287.

PMID: 35902830 PMC: 9330662. DOI: 10.1186/s12890-022-02078-9.


Does synbiotic supplementation affect the quality of life in children with cystic fibrosis? A pilot randomized controlled clinical trial.

Bilan N, Marefat E, Nikniaz L, Farhangi M, Nikniaz Z BMC Nutr. 2020; 6:44.

PMID: 33072395 PMC: 7559449. DOI: 10.1186/s40795-020-00373-4.


EVALUATION OF NUTRITIONAL STATUS IN PATIENTS WITH CYSTIC FIBROSIS ACCORDING TO AGE GROUP.

Lopes Neri L, Bergamaschi D, Silva Filho L Rev Paul Pediatr. 2018; 37(1):58-64.

PMID: 30110111 PMC: 6362381. DOI: 10.1590/1984-0462/;2019;37;1;00007.


A Metagenomic and in Silico Functional Prediction of Gut Microbiota Profiles May Concur in Discovering New Cystic Fibrosis Patient-Targeted Probiotics.

Vernocchi P, Del Chierico F, Quagliariello A, Ercolini D, Lucidi V, Putignani L Nutrients. 2017; 9(12).

PMID: 29232848 PMC: 5748792. DOI: 10.3390/nu9121342.


Does probiotic supplementation affect pulmonary exacerbation and intestinal inflammation in cystic fibrosis: a systematic review of randomized clinical trials.

Nikniaz Z, Nikniaz L, Bilan N, Somi M, Faramarzi E World J Pediatr. 2017; 13(4):307-313.

PMID: 28470579 DOI: 10.1007/s12519-017-0033-6.